By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later ...

Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

HYDERABAD — Dr Reddy’s Laboratories is gearing up to enter the booming global obesity drug market with a more affordable ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Novo Nordisk shares fell significantly due to pressure from U.S. President Donald Trump to cut drug prices, and competition ...